Introduction Selecting between an integrated contract development and manufacturing organization (CDMO) and multiple specialized vendors depends on whether a drug […]
Is It Better to Use One Integrated CDMO or Multiple Specialized Vendors? Read More »
Introduction Glycan profiling analysis for biosimilar characterization provides valuable insights into how critical N-glycoforms, particularly afucosylation, sialylation, and high mannose
Introduction Higher Order Structure Analysis for Biosimilar Characterization is essential because proteins with identical primary amino acid sequences can adopt
Introduction: Clinical Trial Material Manufacturing for Phase I and II is a critical part of drug development because clinical studies
Clinical Trial Material Manufacturing at a CDMO: Phase I and II Supply Planning Read More »
Introduction Intact Mass Analysis for Biosimilar Characterization is a fundamental bioanalytical technique used to determine the total mass of a
Introduction Functional assays for biosimilar characterization are essential for evaluating analytical bioequivalence, biological potency, and mechanism-driven functional comparability between proposed
Introduction Peptide Analytical Method Development and Validation is a critical component of peptide drug development because peptide molecules present analytical
Peptide Analytical Method Development and Validation Services under ICH Q2(R2) and Q14 Read More »
Introduction Glycosylation Profiling for Biosimilar Characterization establishes the structural, physicochemical, and functional comparability of complex oligosaccharide structures attached to therapeutic
Introduction Physicochemical Assessment for Biosimilar Characterization involves a comprehensive, multi-tiered analytical examination of the structural, chemical, and biophysical quality attributes
Introduction Modern biosimilar development increasingly depends on high-resolution structural and functional data as the principal surrogate for demonstrating therapeutic equivalence.
